Preparation and application of tumor immune microenvironment regulating agent

Abstract

The invention provides a tumor immune microenvironment regulating agent which consists of the following components: a protective agent and crushed poecilobdella manillensis. The protective agent comprises the following components: 5% of skimmed milk powder, cane sugar, vitamin C, propolis and glycerol. Further, the ratios of all raw material in the protective agent, i.e., mass volume ratios of all the raw material to normal saline, respectively are that: the ratio of the skimmed mild powder is 5%, the ratio of the cane sugar is 3%, the ratio of the vitamin C is 0.5%, the ratio of the propolis is 0.1% and the ratio of the glycerol is 8%. According to the invention, positive immunization can be driven by regulating and controlling a tumor immune microenvironment, i.e., the infiltration ratios of CD8-positive T-lymphocytes (CD8+T) and natural killer cells (NK) in the tumor microenvironment are increased, and M1 type tumor immune macrophages (TAM) are inhibited so as to enhance sensitivity of the anti-tumor effect of an immune checkpoint inhibitor (ICI) such as drugs of pembrolizumab, nivolumab and the like, and improve the overall response rate (ORR) of the ICI in solid tumor treatment.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to the preparation and application of a tumor immune microenvironment regulator. Background technique [0002] In recent years, the application and research of immune checkpoint inhibitors (immune checkpoint inhibitors, ICI) in the treatment of solid tumors are in full swing. OPDIVO) has been approved by FAD for the treatment of multiple solid tumors. There are also several similar drugs in China such as Tyvyt (sintilimab injection) and Tuoyi (toripalimab) on the urinary tract. However, without biomarker screening (such as TMB, PD-L1, dMMR / MSI-H and other biomarkers), ICI single Drug treatment of solid tumors, the effective rate of each tumor type is basically below 30%, and after screening, even if the effective rate is improved, the proportion of potential responding patients that can be screened is very small, for example, in colorectal cancer Although such patients wit...

AI Technical Summary

Problems solved by technology

However, this type of combination therapy increases the risk of side effects on the one hand, and increases the cost of medication for patients on the other hand. Therefore, the present invention prepares a new adjuvant that can regulate the tumor immune microenvironment, which is used to sensitize ICI to treat pan- Solid tumors, enabling more patients with solid tumors to benefit from ICI treatment

Images